ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1684

Cost Effectiveness Study of Hyperkalemia Management

Session Information

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology


  • Desai, Nihar, Yale University, Center for Outcomes Research and Evaluation, New Haven, Connecticut, United States
  • Rowan, Christopher G., COHRDATA, Santa Monica, California, United States
  • Alvarez, Paula J., Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Fogli, Jeanene, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Coca, Steven G., Icahn School of Medicine at Mount Sinai, New York, New York, United States

Patiromer (PAT) is a sodium-free, non-absorbed potassium (K+) binder approved for the treatment of hyperkalemia (HK). There is limited real-world evidence on the cost implications associated with PAT treatment of HK. The objective of this study was to assess the cost-effectiveness of treating HK with PAT vs. no K+ binder in a Medicare Advantage population.


This retrospective, matched cohort study was conducted using the de-identified Optum Clinformatics® Data Mart Database from 1/1/16–12/31/18. Two HK cohorts were identified: PAT exposed and unexposed (NoPAT). Patient inclusion criteria included pre-index serum K+ ≥5.0 mEq/L and HK diagnosis (ICD-10 code) and ≥6 months insurance enrollment post-index. Propensity score matching and coarsened exact matching with baseline variables were used to identify the complete set of matching unexposed and exposed HK episodes. Follow-up began on index date and ended at the first censoring event (insurance disenrollment, death, 12/31/18, sodium polystyrene sulfonate or sodium zirconium cyclosilicate initiation, PAT discontinuation [exposed only], PAT initiation [unexposed only]). Cost outcomes measured at 6 months post-index: total, inpatient, emergency department (ED), outpatient services and outpatient pharmacy (mean US$ [CI 95%]).


The study population was 2004 patients (1002 matched pairs). Overall, mean age was 74 years and 60% were male. Patients had a mean of 5 comorbidities. Comorbidities included: DM (73%), CHF (35%), and ESRD (10%). At 6 months post-index, 300 (150 matched pairs) PAT and NoPAT patients remained uncensored. Total PAT mean cost difference (savings) of $7220 ($2211,$9584) was observed at 6 months post-index (P<0.01). This cost difference included a pharmacy increase of $3094 ($3964,$2224) and a decrease in medical costs, specifically, inpatient $4718 ($2222,$7215), outpatient $4781 ($2274,$7288), and ED $815 ($488,$1142).


At 6 months post-index, PAT cohort observed a 27% reduction in cost compared with the unexposed cohort for HK management. Further study is warranted to replicate these findings in a large cohort.